Welcome to our dedicated page for Envista Holdings news (Ticker: NVST), a resource for investors and traders seeking the latest updates and insights on Envista Holdings stock.
Envista Holdings Corporation reports recurring developments as a global dental products company serving dental professionals through consumables, technologies, equipment and services. Its public updates center on quarterly results, core sales trends, adjusted earnings measures, cash flow, share repurchase activity and management presentations at healthcare conferences.
Company news also covers product and brand activity across DEXIS, Kerr, Nobel Biocare and Ormco, including dental implants, orthodontics, digital imaging, restorative and endodontic solutions. Recent product announcements include Kerr Dental's ZenSeal Pro with ZenSave Tips, reflecting Envista's focus on dental workflow, treatment technology and clinician-facing product commercialization.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Envista Holdings Corporation (NYSE: NVST) will release its first-quarter 2023 financial results on May 3, 2023. A conference call discussing these results is scheduled for the same day at 2:00 PM PT, lasting approximately one hour. The call will be accessible via a dial-in number and will also be webcast on the company's website. Post-presentation, a replay will be available for one year. Envista is a leading global dental products company, supporting professionals with a diverse portfolio that includes dental implants, orthodontics, and digital imaging technologies.
Envista Holdings Corporation (NYSE: NVST) has announced the registration for its third annual Envista Summit, to be held in Anaheim, California, from February 15-17, 2024. The event aims to unite the dental community, showcasing innovations and workflow improvements through presentations and hands-on workshops. The successful 2023 Summit in Las Vegas attracted nearly 1,500 professionals, featuring over 100 experts and extensive training sessions. Envista's CEO, Amir Aghdaei, emphasizes the goal of empowering dental practices through advanced tools and knowledge. Registrants can earn continuing education credits while enhancing patient care and operational efficiency.
Summary not available.
Envista Holdings Corporation (NYSE: NVST) reported a 1.4% increase in sales to $660.8 million for Q4 2022, with core sales growth of 2.3% year-over-year. Net income reached $73.5 million, or $0.42 per diluted share, while adjusted net income rose to $91.9 million ($0.52 per diluted share), up from $81.1 million ($0.46) in Q4 2021. Adjusted EBITDA was $138.3 million, compared to $120.7 million the previous year. For 2023, Envista anticipates low-single digit core sales growth and an adjusted EBITDA margin exceeding 20%.
On January 30, 2023, Envista Holdings Corporation (NYSE: NVST) announced an Investor Access Event scheduled for February 24, 2023, from 8:00 am to 10:00 am PT at the Envista Summit. This hybrid event will feature a management presentation followed by a Q&A session. The Envista Summit aims to provide dental professionals with premium training across specialties like implantology, orthodontics, and endodontics, alongside digital dentistry training. For further details, visit the Envista Summit website.
Envista Holdings Corporation (NYSE: NVST) is set to report its fourth quarter 2022 financial results on February 8, 2023. A conference call to discuss these results will begin at 2:00 PM PT, lasting approximately one hour. The call will be accessible via the company's website, and a replay will be available shortly after. Envista, recognized for its extensive range of dental brands like Nobel Biocare and Ormco, focuses on enhancing patient care with innovative dental solutions and technologies, making it a significant player in the global dental products market.